<DOC>
	<DOC>NCT00139750</DOC>
	<brief_summary>The purpose of the study is to examine the safety and efficacy and dose-response relationship of three doses of CP-526,555 for 12 weeks compared with placebo for smoking cessation; including post-treatment follow-up of smoking status to one year from randomization. A small satellite protocol (A3051048) investigated safety of a second course of therapy in subjects who did not quit.</brief_summary>
	<brief_title>12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation</brief_title>
	<detailed_description />
	<mesh_term>Varenicline</mesh_term>
	<criteria>Cigarette smokers who are motivated to stop smoking and have smoked an average of at least 10 cigarettes per day Subjects who have used a nicotine replacement product within 30 days of the study screening visit or intend to use it during the study.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>